Areteia Therapeutics, spun out of Pennsylvania-based Knopp, is a clinical-stage biotechnology company dedicated to improving asthma management. The company's mission is to enhance the quality of life for asthma patients by developing innovative treatments, including the first potential oral drug for eosinophilic asthma. Their core focus is on addressing the needs of patients with severe and hard-to-treat asthma, a condition affecting millions globally.
Notable affiliated individuals include scientists and executives from Knopp who have contributed to the development of Areteia's drug candidate. The company has achieved significant milestones, such as publishing promising phase 2 clinical trial results demonstrating the efficacy of their oral drug in reducing blood eosinophil counts and improving lung function. Areteia Therapeutics aims to make a substantial impact on global healthcare by providing effective solutions for asthma management.
